Latest 5-HT2A receptor Stories
We the People and our synaptic serotonin systems are the focus found in four 2015 (short) science tales from the National Institutes of Health (PubMed). In today’s update, author Bryan W.
- AMAP102 falls short of primary endpoint in exploratory Phase 2a study - GOTHENBURG, Sweden, Oct.
For more than a decade the research group of Brown University Professor Walter Atwood has doggedly pursued the workings of the JC polyomavirus, which causes a disease called PML that fatally degrades the central nervous system of patients with weakened immune systems.
Scripps Research Institute scientists have shown for the first time that the neurotransmitter serotonin uses a specialized signaling pathway to mediate biological functions that are distinct from the signaling pathways used by hallucinogenic substances.
NEW YORK, Dec. 21 /PRNewswire/ -- Intra-Cellular Therapies, Inc.
SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. today announced positive results from a multiple-ascending dose Phase 1b clinical trial of APD791 to evaluate the compound's safety, pharmacokinetics and pharmacodynamics.
Swiss chemist Albert Hofmann, who discovered the hallucinogenic drug LSD, died yesterday. But the LSD trip is far from over as scientists bring lucidity to how hallucinogens work.
- Growing in low tufty patches.